PVCT — Provectus Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $26.86m
- $29.07m
- $0.62m
Annual cashflow statement for Provectus Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.68 | -5.54 | -3.55 | -3.1 | -4.76 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.208 | 0.042 | 0.056 | 0.048 | 1.33 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.14 | 4.47 | 0.446 | 0.473 | 0.143 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.09 | -1.01 | -3.04 | -2.57 | -3.28 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.6 | 4.02 | 1.37 | 2.19 | 2.75 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.493 | 3.01 | -1.68 | -0.405 | -0.537 |